Digital Public Defence: Gry Dahle

MD Gry Dahle at Institute of Clinical Medicine will be defending the thesis “The Introduction of Transcatheter Aortic Valve Implantation (TAVI) - Clinical, patient experience, economical and occupational hazard issues” for the degree of PhD (Philosophiae Doctor).

Image may contain: Person, Face, Chin, Portrait, Forehead.

Photo: Amalie Huth Hovland, UiO.

The University of Oslo arranges all public defences digitally this semester, thus the disputation will be held as a video conference over Zoom.

The public defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.

Click here to participate in the public defence

Download Zoom here


Digital Trial Lecture – time and place

See Digital Trial Lecture.

Adjudication committee

  • First opponent: Professor Ottavio Alfieri, San Rafaele Hospital, Italy
  • Second opponent: Professor Leif Thuesen, Aalborg University Hospital, Denmark
  • Third member and chair of the evaluation committee: Professor II Drude Fugelseth, University of Oslo

Chair of the Defence

Professor II Marit Lieng, University of Oslo 

Principal Supervisor

Professor II Erik Fosse, University of Oslo


Innovation is a natural process in the evolution of health service to the society. It involves many stakeholders such as the patients, the physicians, the payers, the politicians, the engineers, the regulators, the scientific societies etc.

When introducing a new treatment option, it is of great importance to study the value of the new therapy both in a patient as well as a societal perspective at an early stage as possible. Thus, this study aimed at investigating and elucidating the cost of the new TAVI treatment, the objective results in heart function and complications, the quality of life for the patients and the hazards for the personnel in the hybrid operation room.

Objective measurements on health improvements in cardiac patients are in this study defined as quality of life and New York Heart Association (NYHA) functional class. Costs, changes in quality of life and clinical outcomes were recorded from the first day, and a clear picture of the potential value outcomes was obtained. As treatment initially was offered to patients with advanced disease, a number of patients were observed who did not benefit from the treatment.

A better selection is mandatory in order to save patients from a non-beneficial treatment and the burden of an unnecessary intervention.  Our findings indicate that it may be possible to improve the selection, but further studies are warranted.

TAVI may have a great impact on hospital budget in the future, but if the value for the patient increases, the innovation may be justified.

Additional information

Contact the research support staff.

Published June 10, 2020 3:54 PM - Last modified June 25, 2020 12:58 PM